Qingdao Navid Biotechnology Co., Ltd.

Qingdao Navid Biotechnology Co. , Ltd. is a biotechnology company focused on pioneering nucleic acid rapid detection technology, offering innovative solutions for point-of-care testing across various industries including healthcare and food safety. Founded in 2016 in Qingdao, China, Qingdao Navid Biotechnology Co.

, Ltd. specializes in nucleic acid rapid detection technology. The company has successfully conducted two investment rounds, with their most recent funding occurring in January 2022 when they raised CNY 10 million. The company is led by CEO Chao Shi, who has a history in the biotechnology sector.

Qingdao Navid Biotechnology Co. , Ltd. specializes in the research and development of nucleic acid rapid detection technology, primarily focusing on point-of-care testing (POCT) solutions. The company’s core offerings include sample release agents, nucleic acid extraction reagents, disposable virus sampling tubes, and detection kits for various pathogens, including those responsible for food safety, animal health, and medical diagnostics.

Their flagship products leverage a unique isothermal nucleic acid detection technology, which allows for rapid and simplified testing processes, making them suitable for diverse applications including in vitro diagnostics, agricultural safety, and aquaculture. Target customers encompass a broad spectrum of industries, including academic and scientific research institutions, food safety regulators, healthcare providers, and animal husbandry sectors. The company markets its products globally, with a particular emphasis on regions demanding advanced molecular diagnostic solutions. Qingdao Navid Biotechnology Co.

, Ltd. generates revenue through direct sales of its diversified product portfolio, primarily to businesses and institutions engaged in healthcare, food safety, and animal husbandry. The company operates under a direct-to-consumer model, providing its advanced POCT products and supporting instruments directly to end-users and institutional clients. Transactions typically involve bulk orders, with clients purchasing the products based on specific needs for testing and detection.

The pricing structure reflects the technological advancement and efficacy of their products, catering to various clients such as hospitals, universities, and agricultural enterprises. The integration of their proprietary technology into user-friendly platforms enhances market appeal, driving customer engagement and loyalty across both domestic and international markets. In January 2022, Qingdao Navid Biotechnology Co. , Ltd.

raised CNY 10 million in venture funding from new investor Qingdao Gaochuang Investment, with participation from returning investor Milestone Capital. The company plans to utilize this funding for the research and development of handheld nucleic acid testing solutions and the promotion of an integrated quick inspection system. Additionally, Qingdao Navid aims to expand its market presence in Southeast Asia and Europe by the end of 2023, targeting regions with growing demands for advanced molecular diagnostics.